Skip to main content
Edwards Lifesciences Logo

Magna Mitral Ease valve

mitral pericardial
THV banner

Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve

Built upon the unique and proven PERIMOUNT valve design, the Magna Mitral Ease valve gives you and your patients:

  • Ultra-low profile, with reduced ventricular projection by up to 40%‡
  • Exceptional long-term durability1-8
  • Ease of implant

The Magna Mitral Ease valve is built upon the proven, time-tested PERIMOUNT valve design, with unique design elements including:

  • Mathematically modeled, bioengineered design. Intended to optimize implantability, hemodynamics and long-term durability
  • Flexible cobalt-chromium alloy stent. Absorbs energy to reduce leaflet stress
  • Three independent bovine pericardial leaflets. Matched for thickness and elasticity to optimize stress distribution

‡ As compared to the Carpentier-Edwards PERIMOUNT Theon mitral valve.

1 / 3
perimount mitral
Ease of implant
Exceptional long-term durability
perimount mitral
Ease of implant
Exceptional long-term durability

Model 7300TFX

Ease of implant

Wide, contoured cuff with unique anterior saddle and lateral contour to mimic the shape of the native mitral anatomy

Exceptional long-term durability

Magna Mitral Ease heart valve

Model 7300TFX Nominal Specifications (mm)Size 25Size 27Size 29Size 31Size 33
1. Inflow Orifice Diameter (mm)23.025.027.029.029.0
2. Effective Orifice Diameter (mm)18.020.022.022.522.5
3. Stent Diameter (Wireform, mm) 2527293131
4. External Stent Post Diameter (Tip, mm)2931343535
5. Valve Housing External Diameter (mm)27.529.531.533.533.5
6. External Sewing Ring Diameter (mm)36.037.540.042.044.5
7. Effective Profile Posterior (mm)1010.51111.511.5
8. Effective Profile Anterior (mm)  77.588.58.5
9. Total Profile Height (mm)1516171818
model 7300FTX

References

  1. Aupart MR, Neville PH, Hammami S, et al. Carpentier-Edwards pericardial valves in the mitral position: ten-year follow-up. J Thorac Cardiovasc Surg. 1997;113(3):492-498. doi: 10.1016/S0022-5223(97)70361-1 (Freedom from structural deterioration; n = 150; mean age = 62.9 ± 11.9 yrs)
  2. Jamieson WRE, Marchand MA, Pelletier CL, et al. Structural valve deterioration in mitral replacement surgery: comparison of Carpentier-Edwards supra-annular porcine and perimount pericardial bioprostheses. J Thorac Cardiovasc Surg. 1999;118(2):297-304. doi: 10.1016/S0022-5223(99)70220-5 (Freedom from explant due to structural valve deterioration; n = 429; mean age = 60.7 ± 11.7 yrs)
  3. Murakami T, Eishi K, Nakano S, et al. Aortic and mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 10-year results. J Heart Valve Dis. 1996;5(1):45-49. (Freedom from structural deterioration; n = 57; mean age = 55.1 ± 13.2 yrs)
  4. Poirer NC, Pelletier LC, Pellerin M, et al.  15-year experience with the Carpentier-Edwards pericardial bioprosthesis. Ann Thorac Surg. 1998;66(6 Suppl):S57-S61. doi:10.1016/s0003-4975(98)01110-2 (Freedom from structural deterioration; n = 214; mean age = 65 ± 23 yrs)
  5. Neville PH, Aupart MR, Diemont FF, et al. Carpentier-Edwards pericardial bioprosthesis in aortic or mitral position: a 12-year experience. Ann Thorac Surg. 1998;66(6 Suppl):S143-S147. doi: 10.1016/s0003-4975(98)01122-9 (Freedom from structural deterioration; n = 182; mean age = 63.9 ± 11.5 yrs)
  6. Marchand MA, Aupart MR, Norton R, et al. Fifteen-year experience with the mitral Carpentier-Edwards PERIMOUNT pericardial bioprosthesis. Ann Thorac Surg. 2001;71(5 Suppl):S236-S239. doi: 10.1016/s0003-4975(01)02550-4 (Freedom from structural valve deterioration; n = 435; mean age = 60.7 ± 11.6 yrs)
  7. Bourguignon T, Bouquiaux-Stablo AL, Loardi C, et al. Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg. 2014;148(5):2004-2011.e1. doi: 10.1016/j.jtcvs.2014.02.050 (Freedom from explant due to structural valve deterioration; n = 404; mean age = 68.0 ± 10.4 yrs)
  8. Carpentier-Edwards PERIMOUNT pericardial bioprosthesis 16-year results. Data on file at Edwards Lifesciences, 2003. (Freedom from explant due to structural valve deterioration; n = 435; mean age = 60.7 ± 11.6 yrs)
Important Safety Information

Important Safety Information

Carpentier-Edwards PERIMOUNT Mitral Bioprostheses

Indications: For use in patients whose mitral valvular disease warrants replacement of their natural or previously placed prosthetic mitral valve. 

Contraindications: Do not use if surgeon believes such would be contrary to the patient’s best interests. 

Complications and Side Effects: Stenosis, regurgitation, endocarditis, hemolysis, thromboembolism, valve thrombosis, nonstructural dysfunction, structural valve deterioration, anemia, arrhythmia, hemorrhage, transient ischemic attack/ stroke, congestive heart failure, myocardial infarction, angina, ventricular perforation by stent posts any of which could lead to reoperation, explantation, permanent disability, and death.

CAUTION: USA law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information.